Nocion Therapeutics

Executive Summary

Nocion Therapeutics is a clinical-stage biopharmaceutical company developing novel, non-opioid treatments for cough, itch, and pain. Its platform targets nociceptive ion channels to create peripherally-acting agents that block disease signals at the source, thereby avoiding central nervous system side effects commonly associated with opioids and other pain medications. Founded in 2018 and based in Cambridge, MA, the company has raised $62 million to advance its lead programs through Phase 2 trials. Nocion's lead candidate, NTX-001, is being evaluated for chronic cough and neuropathic itch, addressing significant unmet needs in conditions where existing therapies are limited or have poor tolerability. By focusing on peripheral targets, Nocion aims to provide effective symptom relief without sedation, addiction potential, or other CNS liabilities. The company's approach leverages a deep understanding of nociceptor biology and has shown promising preclinical and early clinical results. With a strong intellectual property portfolio and a seasoned management team, Nocion is positioned to become a leader in non-opioid pain and sensory disorder therapeutics. Success in ongoing trials could address multi-billion-dollar markets and offer safer alternatives to current standard of care.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 topline data for NTX-001 in chronic cough80% success
• Q4 2026Potential strategic partnership or licensing deal50% success
• Q1 2027Series C funding round60% success